417 related articles for article (PubMed ID: 36054614)
21. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
[TBL] [Abstract][Full Text] [Related]
22. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
Kövy P; Őrfi Z; Bors A; Kozma A; Gopcsa L; Dolgos J; Lovas N; Harasztdombi J; Lakatos V; Király Á; Mikala G; Vályi-Nagy I; Reményi P; Andrikovics H
PLoS One; 2021; 16(6):e0253386. PubMed ID: 34153064
[TBL] [Abstract][Full Text] [Related]
23. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
Bill M; Jentzsch M; Bischof L; Kohlschmidt J; Grimm J; Schmalbrock LK; Backhaus D; Brauer D; Goldmann K; Franke GN; Vucinic V; Niederwieser D; Mims AS; Platzbecker U; Eisfeld AK; Schwind S
Blood Adv; 2023 Feb; 7(3):436-444. PubMed ID: 35381077
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
Ravandi F; Patel K; Luthra R; Faderl S; Konopleva M; Kadia T; Brandt M; Pierce S; Kornblau S; Andreeff M; Wang X; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2012 May; 118(10):2665-73. PubMed ID: 22020636
[TBL] [Abstract][Full Text] [Related]
25. Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation.
Raveendran S; Sarojam S; Vijay S; Geetha AC; Sreedharan J; Narayanan G; Sreedharan H
Asian Pac J Cancer Prev; 2015; 16(9):4095-101. PubMed ID: 25987093
[TBL] [Abstract][Full Text] [Related]
26. [Effects of IDH2 Gene Mutation on Clinical Characteristics and Prognostic of Patients with Acute Myeloid Leukemia].
Luo LQ; Peng ZY; Liu X; Yu WZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1077-1082. PubMed ID: 31418360
[TBL] [Abstract][Full Text] [Related]
27. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
Zarnegar-Lumley S; Alonzo TA; Gerbing RB; Othus M; Sun Z; Ries RE; Wang J; Leonti A; Kutny MA; Ostronoff F; Radich JP; Appelbaum FR; Pogosova-Agadjanyan EL; O'Dwyer K; Tallman MS; Litzow M; Atallah E; Cooper TM; Aplenc RA; Abdel-Wahab O; Gamis AS; Luger S; Erba H; Levine R; Kolb EA; Stirewalt DL; Meshinchi S; Tarlock K
Blood Adv; 2023 Oct; 7(19):5941-5953. PubMed ID: 37267439
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
29. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
[TBL] [Abstract][Full Text] [Related]
30. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
Zhou KG; Jiang LJ; Shang Z; Wang J; Huang L; Zhou JF
Leuk Lymphoma; 2012 Dec; 53(12):2423-9. PubMed ID: 22616558
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
Leuk Res; 2022 Nov; 122():106942. PubMed ID: 36108424
[TBL] [Abstract][Full Text] [Related]
33. IDH mutations in acute myeloid leukemia.
Rakheja D; Konoplev S; Medeiros LJ; Chen W
Hum Pathol; 2012 Oct; 43(10):1541-51. PubMed ID: 22917530
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
Leuk Lymphoma; 2023 Jan; 64(1):188-196. PubMed ID: 36287540
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
36. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
Pollyea DA; DiNardo CD; Arellano ML; Pigneux A; Fiedler W; Konopleva M; Rizzieri DA; Smith BD; Shinagawa A; Lemoli RM; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Kantarjian HM
Clin Cancer Res; 2022 Jul; 28(13):2753-2761. PubMed ID: 35046058
[TBL] [Abstract][Full Text] [Related]
37. [Effect of clonal hematopoiesis in remission on hematopoiesis recovery in patients with NPM1 mutated acute myeloid leukemia after chemotherapy].
Wang LL; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):845-850. PubMed ID: 38049337
[No Abstract] [Full Text] [Related]
38. Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.
Papadopoulou V; Schoumans J; Basset V; Solly F; Pasquier J; Blum S; Spertini O
Hematology; 2023 Dec; 28(1):2180704. PubMed ID: 36815747
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract][Full Text] [Related]
40. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
